Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

Autor:	Argyrios Ntalianis, Ioannis Ntanasis-Stathopoulos, Charikleia Gakiopoulou, Meletios A. Dimopoulos, Asimina Papanikolaou, Evangelos Eleutherakis-Papaiakovou, Kimon Stamatelopoulos, Marylin Spyropoulou-Vlachou, Nikolaos Kanellias, Maria Gavriatopoulou, Alexandra Papathoma, Despina Fotiou, Efstathios Kastritis, Erasmia Psimenou, Magdalini Migkou, Eleni A. Karatrasoglou, Maria Roussou, Foteini Theodorakakou, Maria Irini Tselegkidi, Ioanna Dialoupi, Evangelos Terpos
Rok vydání:	2020
Předmět:	Adult Male medicine.medical_specialty 030204 cardiovascular system & hematology Gastroenterology Disease-Free Survival Primary therapy Bortezomib 03 medical and health sciences 0302 clinical medicine Internal medicine Natriuretic Peptide Brain Internal Medicine medicine AL amyloidosis Humans Immunoglobulin Light-chain Amyloidosis In patient Aged Aged 80 and over Proteinuria business.industry Middle Aged medicine.disease Peptide Fragments Female Immunoglobulin Light Chains medicine.symptom business 030217 neurology & neurosurgery medicine.drug
Zdroj:	Amyloid. 28:3-11
ISSN:	1744-2818 1350-6129
DOI:	10.1080/13506129.2020.1798224
Popis:	A rapid and deep haematologic response is fundamental in order to improve outcomes of patients with AL amyloidosis. We evaluated the impact of timing and depth of haematologic response at early time points (at 1 and 3 months from the start of therapy) in 227 consecutive previously untreated AL patients, who received bortezomib-based primary therapy. After 1 month of therapy, 30.5% had ≥VGPR, 28% PR and 36% no response (NR), with 11% having iFLC
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219dbdceb19af1bdbf6c88542801ed0d https://doi.org/10.1080/13506129.2020.1798224 Zobrazit plný text záznamu